Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

Johnson & Johnson (NYSE:JNJ) reported a fourth-quarter adjusted EPS of $2.04, down 10.9% year over year, beating the ...

Titusville: Johnson & Johnson has announced the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO (esketamine) CIII nasal spray, ...